Real-World Studies
Dual checkpoint blockade yields 16.7% response rate in advanced sarcoma cohort
Snyder et alThe oncologist
A single-institution retrospective analysis evaluated real-world outcomes for 90 patients with advanced, metastatic, or unresectable sarcoma treated with the immune checkpoint inhibitor combination ipilimumab and nivolumab between 2019 and 2024. Responses were assessed using iRECIST criteria, and survival outcomes were analyzed via the Kaplan-Meier method to evaluate the real-world clinical utility of dual immune checkpoint blockade across varied sarcoma subtypes, including ultra-rare histologies.
Among evaluable patients, combination therapy achieved an objective response rate (ORR) of 16.7% and a clinical benefit rate (CBR) of 30.0%. Best overall responses comprised partial response in 14.4% of patients, stable disease in 23.3%, and progressive disease in 62.2%. For patients who achieved an objective response, median overall survival (OS; 95% CI, 14.4 months to not estimated) and median progression-free survival (PFS; 95% CI, 9.6 months to not estimated) were not reached.
Histologic subgroup analysis revealed the highest ORRs in angiosarcoma, malignant peripheral nerve sheath tumors (MPNST), leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), and chondrosarcoma. Safety analysis indicated a positive prognostic correlation with immune-related adverse events (irAEs); patients who developed irAEs demonstrated superior overall survival, with thyroid dysfunction irAEs specifically demonstrating significant superiority in both median PFS and median OS. These findings demonstrate that dual ICI therapy confers meaningful and durable responses in select heavily pretreated sarcoma histologies, with thyroid toxicity serving as a clinical biomarker of survival benefit.
Key Takeaways
- In a real-world retrospective analysis of 90 patients with advanced or unresectable sarcoma, combination ipilimumab and nivolumab achieved an objective response rate of 16.7% and a clinical benefit rate of 30.0%, consisting of partial responses in 14.4% and stable disease in 23.3%.
- Patients achieving an objective response experienced durable disease control, with median overall survival and median progression-free survival not reached, and highest response rates occurred in angiosarcoma, malignant peripheral nerve sheath tumor, leiomyosarcoma, undifferentiated pleomorphic sarcoma, and chondrosarcoma.
- The development of immune-related adverse events was associated with superior overall survival, with thyroid-specific immune-related adverse events significantly correlating with improved overall survival and progression-free survival.
Read the original sourceThe oncologist
